A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01309412
Recruitment Status : Terminated (Protocol was stopped due to the safety issue in Global)
First Posted : March 7, 2011
Last Update Posted : May 19, 2014
Information provided by (Responsible Party):
Janssen Pharmaceutical K.K.

Brief Summary:
The purpose of this study is to assess the safety and the tolerability of siltuximab up to 11.0 mg/kg in combination with bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Siltuximab Phase 1

Detailed Description:
This study is an open-label (both physician and patient know the name of the study drug), multicenter (more than one site) study of siltuximab in patients with relapsed or refractory multiple myeloma receiving siltuximab in combination with bortezomib/dexamethasone to evaluate the safety, pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time), efficacy and immunogenicity (the ability to induce immune responses). This study is planned with a dose escalation of siltuximab to levels of 5.5 mg/kg (Dose Level 1) and 11.0 mg/kg (Dose Level 2) given intravenously. Recommended doses will be determined based on the incidence of dose-limiting toxicity in patients with relapsed or refractory multiple myeloma when siltuximab at dose levels of 5.5 mg/kg and 11.0 mg/kg is administered with bortezomib/dexamethasone. Treatment with siltuximab will be started at Dose Level 1, and treatment at Dose Level 2 will not be started until completing the safety evaluation at the end of the observation period of Cycle 1 for all patients at Dose level 1. Once 11.0 mg/kg is determined as a recommended dose, the dose for patients whose starting dose is 5.5 mg/kg, and who have not achieved complete response, can be escalated to 11.0 mg/kg based on patient consent and investigator discretion in the next cycle. Siltuximab will be given at 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression. Twice-weekly intravenous administration of bortezomib 1.3 mg/m2 (Days 1, 4, 8, and 11) will be followed by a 10-day rest period (Days 12-21). Four-per-week oral administration of dexamethasone 20 mg (Days 1, 2, 4, 5, 8, 9, 11 and 12) will be followed by a 9-day rest period (Days 13-21).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of CNTO 328 (Siltuximab) in Combination With Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma
Study Start Date : January 2011
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Siltuximab

Arm Intervention/treatment
Experimental: Siltuximab
Siltuximab 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
Drug: Siltuximab
5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression

Primary Outcome Measures :
  1. Number of patients with adverse events as a measure of safety and tolerability [ Time Frame: Up to 14 months ]

Secondary Outcome Measures :
  1. Serum siltuximab concentration [ Time Frame: Maximum 15 weeks ]
  2. Number of patients with a positive immune response to siltuximab [ Time Frame: Up to 14 months ]
  3. Number of patients with an overall response (complete response and partial response) [ Time Frame: Up to 14 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients proven to have symptomatic or nonsecretory multiple myeloma
  • Patients with a measurable lesion
  • Patients who have previously received 1-3 regimens for multiple myeloma
  • Patients must have progressed on or be refractory to the most recent line of treatment
  • Patients with Eastern Cooperative Oncology Group performance status of 0-2
  • Patients having the following laboratory values within 14 days before the scheduled day of initial administration of the study drug: hemoglobin 8 g/dL or more, absolute neutrophil count 1,000/mm3 or more, platelet count 50,000/mm3 or more, aspartate aminotransferase, and alanine aminotransferase 2.5 times or more of upper limit of normal range, total bilirubin 1.5 times or more of upper limit of normal range, calculated creatinine clearance 20 mL/min or more, corrected serum calcium less than 12.5 mg/dL

Exclusion Criteria:

  • Patients with primary amyloidosis, plasma cell leukemia or other conditions in which M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
  • Patients with Grade 1 peripheral neuropathy with pain or Grade 2 or higher peripheral neuropathy
  • Patients who have undergone allogeneic bone marrow transplantation within 28 days before the start of treatment with the study drug
  • Patients who have been exposed to agents targeting interleukin-6 (IL-6) or the IL-6 receptor
  • Patients refractory to bortezomib
  • Patients having treatment discontinued because of the toxicity of bortezomib
  • Patients requiring dose reduction because of the toxicity of bortezomib
  • Patients who have received chemotherapy, plasmapheresis or radiation therapy within 21 days before the start of treatment (within 42 days for nitrosoureas)
  • Patients who have undergone major surgery including open biopsy (excluding bone marrow) within 21 days before study treatment or planning to have surgery (except for minor surgical procedures) during the study
  • Human immunodeficiency virus antibody-positive, hepatitis C virus antibody-positive or hepatitis B surface antigen-positive patients
  • Patients with known hypersensitivity to boron or mannitol
  • Patients with a history of unmanageable severe infusion reactions to monoclonal antibodies or to murine, chimeric or human proteins or their excipients
  • Patients with concurrent medical condition that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in the study
  • Patients with significant cardiac disease characterized by significant ischemic coronary disease, significant arrhythmias, or congestive heart failure (New York Heart Association Class III or IV) or myocardial infarction within 6 months before the first dose of study drug
  • Patients who are clinically diagnosed with pneumonitis (interstitial pneumonia) or pulmonary fibrosis or have abnormal interstitial shadows bilaterally on chest CT, with or without symptoms

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01309412

Isehara, Japan
Kyoto, Japan
Nagoya, Japan
Niigata, Japan
Tokyo, Japan
Sponsors and Collaborators
Janssen Pharmaceutical K.K.
Study Director: Janssen Pharmaceutical K.K. Clinical Trial Janssen Pharmaceutical K.K.

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Janssen Pharmaceutical K.K. Identifier: NCT01309412     History of Changes
Other Study ID Numbers: CR017737
JPN-C0328-MM-101 ( Other Identifier: Janssen Pharmaceutical K.K., Japan )
First Posted: March 7, 2011    Key Record Dates
Last Update Posted: May 19, 2014
Last Verified: May 2014

Keywords provided by Janssen Pharmaceutical K.K.:
Relapsed or refractory multiple myeloma
CNTO 328

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunologic Factors